Reports
Sale
Ependymoma Market Size, Share, Analysis, Report, Forecast: By Type: Subependymoma, Myxopapillary Ependymoma, Anaplastic Ependymoma; By Therapy Type: Chemotherapy, Radiation Therapy, Targeted Therapy; By Treatment: Medication, Surgery; By Drugs; Route of Administration; By Distribution Channel; Regional Analysis; 2024-2032
Ependymoma Market Outlook
The ependymoma market size was valued at USD 149.86 million in 2023, driven by the increasing number of research and development activities for new treatments across the 7 major markets. The market size is anticipated to grow at a CAGR of 4.80% during the forecast period of 2024-2032 to achieve a value of USD 228.5 million by 2032.
Ependymoma: Introduction
Ependymoma is a type of brain tumour that starts in the brain or spinal cord. It is also widely known as a primary central nervous system (CNS) tumour. In many types of cancer, genes might be mutated, which can cause the growth and spread of cancer cells. The exact cause of ependymomas is still unknown. Ependymomas can develop anywhere in the CNS but they are often found near the ventricles in the brain and the central canal of the spinal cord. In rare cases, ependymomas can also form outside the CNS, such as in the ovaries. Ependymomas originate from ependymal cells, which are a type of glial cells that support the central nervous system CNS.
Patients with ependymoma in the brain may experience symptoms such as headaches, nausea, vomiting, and dizziness, among others. On the other hand, patients with ependymoma in the spine may experience back pain, numbness, and weakness in their arms, legs, or trunk, along with problems in sexual, urinary, or bowel functions.
Ependymoma Market Analysis
The rising prevalence of the condition and the rise in diagnosis is anticipated to bolster the ependymoma market demand in the coming years. In the United States, it is expected that around 200 children and teenagers will be diagnosed with ependymoma in 2023, which accounts for approximately 5% of all childhood brain cancers. Although ependymoma can occur at any age, it is most common in children under the age of 5. Males are more likely to be affected than females, and it is most prevalent in white and non-Hispanic people. Currently, approximately 13,294 people are living with this tumour in the United States. The relative 5-year survival rate for ependymoma is 83.9%, but it is important to note that many factors can affect prognosis.
The ependymoma market growth is influenced by the increasing number of clinical trials, both ongoing and open for enrollment, particularly at the University of California Health and UCSF, exhibiting an active interest in discovering novel drug treatments. The FDA's recent approvals of new drug treatments for patient suffering from ganglioglioma, astrocytoma, and oligodendrogliomas are also anticipated to aid the growth of the market.
Ependymoma Market Segmentations
Market Breakup by Type
- Subependymoma
- Myxopapillary Ependymoma
- Anaplastic Ependymoma
Market Breakup by Therapy Type
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
Market Breakup by Treatment
- Medication
- Surgery
Market Breakup by Drugs
- Corticosteroids
- Antiseizure Agents
- Others
Market Breakup by Route of Administration
- Oral
- Injectable
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Ependymoma Market Overview
The market growth is driven by the increasing efforts of the market players and researchers towards developing and providing the best clinical treatment possible in the market. The market is witnessing significant growth in the demand for personalised treatment due to the increasing awareness regarding targeted therapies.
The FDA approvals for new treatment therapies and drugs are significantly contributing to the ependymoma market share, leading to the increased demand for more treatments. The market is expected to witness significant growth due to the demand for new chemotherapy, targeted therapy, or immunotherapy drugs, which may also be available and can be a possible treatment option in the market. The growing support in the form of funding actions by the market players and the governments for research and development activities is further driving the demand for new treatments, propelling the market growth.
The United States is substantially leading the market driven by factors such as increased adoption of advanced techniques. It is likely to continue dominating the market in the coming years as well. The presence of rigid healthcare infrastructure, along with the rising awareness about the availability of limited treatments, is propelling the ependymoma market demand.
Ependymoma Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novocure
- EMulate Therapeutics
- Sun Pharmaceutical Industries Ltd
- Zydus Cadila
- Torrent Pharmaceuticals Ltd
- Takeda Pharmaceutical Company
- Validus Pharmaceuticals LLC.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- WOCKHARDT
- Fera Pharmaceuticals
- Novartis AG
- Baxter
- Lupin Pharmaceuticals, Inc.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Therapy Type |
|
| Breakup by Treatment |
|
| Breakup by Drugs |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ependymoma Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ependymoma Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Ependymoma Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Ependymoma Epidemiology Forecast (2017-2032)
5.3.1 Germany Ependymoma Epidemiology Forecast (2017-2032)
5.3.2 France Ependymoma Epidemiology Forecast (2017-2032)
5.3.3 Italy Ependymoma Epidemiology Forecast (2017-2032)
5.3.4 Spain Ependymoma Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Ependymoma Epidemiology Forecast (2017-2032)
5.4 Japan Ependymoma Epidemiology Forecast (2017-2032)
6 Ependymoma Market Overview – 7MM
6.1 Ependymoma Market Historical Value (2017-2023)
6.2 Ependymoma Market Forecast Value (2024-2032)
7 Ependymoma Market Landscape – 7MM
7.1 Ependymoma Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ependymoma Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Treatments
7.2.3 Analysis by Route of Administration
8 Ependymoma Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ependymoma Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Ependymoma Market Segmentation – 7MM
11.1 Ependymoma Market by Type
11.1.1 Market Overview
11.1.2 Subependymoma
11.1.3 Myxopapillary Ependymoma
11.1.4 Anaplastic Ependymoma
11.2 Ependymoma Market by Therapy Type
11.2.1 Market Overview
11.2.2 Chemotherapy
11.2.3 Radiation Therapy
11.2.4 Targeted Therapy
11.3 Ependymoma Market by Treatment
11.3.1 Market Overview
11.3.2 Medication
11.3.3 Surgery
11.4 Ependymoma Market by Drugs
11.4.1 Market Overview
11.4.2 Corticosteroids
11.4.3 Antiseizure Agents
11.4.4 Others
11.5 Ependymoma Market by Route of Administration
11.5.1 Market Overview
11.5.2 Oral
11.5.3 Injectable
11.6 Ependymoma Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.7 Ependymoma Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Ependymoma Market
12.1 Ependymoma Market Historical Value (2017-2023)
12.2 Ependymoma Market Forecast Value (2024-2032)
12.2.1 Ependymoma Market by Disease Type
12.2.2 Ependymoma Market by Treatment Type
13 EU-4 and United Kingdom Ependymoma Market
13.1 Ependymoma Market Historical Value (2017-2023)
13.2 Ependymoma Market Forecast Value (2024-2032)
13.3 Germany Ependymoma Market Overview
13.3.1 Ependymoma Market by Disease Type
13.3.2 Ependymoma Market by Treatment Type
13.4 France Ependymoma Market Overview
13.4.1 Ependymoma Market by Disease Type
13.4.2 Ependymoma Market by Treatment Type
13.5 Italy Ependymoma Market Overview
13.5.1 Ependymoma Market by Disease Type
13.5.2 Ependymoma Market by Treatment Type
13.6 Spain Ependymoma Market Overview
13.6.1 Ependymoma Market by Disease Type
13.6.2 Ependymoma Market by Treatment Type
13.7 United Kingdom Ependymoma Market Overview
13.7.1 Ependymoma Market by Disease Type
13.7.2 Ependymoma Market by Treatment Type
14 Japan Ependymoma Market
14.1 Ependymoma Market Historical Value (2017-2023)
14.2 Ependymoma Market Forecast Value (2024-2032)
14.3 Ependymoma Market by Disease Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Novocure
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 EMulate Therapeutics
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Sun Pharmaceutical Industries Ltd
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Zydus Cadila
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Torrent Pharmaceuticals Ltd
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Takeda Pharmaceutical Company
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Validus Pharmaceuticals LLC.
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Mylan N.V.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Teva Pharmaceutical Industries Ltd.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 WOCKHARDT
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Fera Pharmaceuticals
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Novartis AG
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Baxter
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Lupin Pharmaceuticals, Inc.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
21 Ependymoma Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 149.86 million in 2023 in the 7 major markets, driven by the increased demand for treatments.
The market is anticipated to grow at a CAGR of 4.80% during the forecast period of 2024-2032, likely to reach a market value of USD 228.5 million by 2032.
The rising healthcare infrastructure, increasing focus of researchers and market players to develop new and effective treatments are among the major factors driving the market growth.
The United States Food and Drug Association (FDA) nodding for new treatments leading to increased demand for treatments is a major trend influencing the market growth.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 is divided into Germany, France, Italy, and Spain.
Ependymoma includes subependymoma, myxopapillary ependymoma, and anaplastic ependymoma.
Treatment therapies available in the market include chemotherapy, radiation therapy, and targeted therapy.
Treatments available in the market are medication and surgery.
Drugs available in the market are corticosteroids and antiseizure agents, among others.
Oral and injectables are the routes of administration in the market.
Distribution channels the market include hospital pharmacy and retail pharmacy.
Key players involved in the market are Novocure, EMulate Therapeutics, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Torrent Pharmaceuticals Ltd, Takeda Pharmaceutical Company, Validus Pharmaceuticals LLC., Mylan N.V., Teva Pharmaceutical Industries Ltd., WOCKHARDT, Fera Pharmaceuticals, Novartis AG, Lupin Pharmaceuticals, Inc., and Baxter.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER